Humanized antibodies that sequester abeta peptide

a technology of humanized antibodies and abeta peptides, which is applied in the field of humanized antibodies, can solve the problems of antibody not having the properties, interfere with plaque formation, and reduce plaque burden, and achieve the effects of inhibiting the toxic effects of soluble a, enhancing the net efflux from the brain, and enhancing the removal of the body
US20060039906A1Inactive Publication Date: 2006-02-23HOLTZMAN DAVID +5
15 Cites 34 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
HOLTZMAN DAVID
Publication Date
2006-02-23
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 10 / 226,435, filed Aug. 22, 2002, which is a continuation of PCT patent application PCT / US01 / 06191, filed Feb. 26, 2001, which was published in English and designated the United States and which claims the priority of U.S. provisional applications 60 / 184,601, filed Feb. 24, 2000, 60 / 254,465, filed Dec. 8, 2000, and 60 / 254,498, filed Dec. 8, 2000, the contents of which are all incorporated herein by reference.TECHNICAL FIELD

[0002] The invention relates to humanized antibodies that bind to an epitope between amino acids 13 and 28 of the Aβ peptide and to preventive and therapeutic treatment of conditions associated with beta amyloid, such as Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathey. More specifically, it concerns use of humanized monoclonal antibodies to sequester amyloid beta (Aβ) peptide in plasma, brain, and cerebrospinal fluid to preve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More